← Back
Data updated: Mar 10, 2026
ETHYPHARM
Infectious DiseaseCardiovascularGastroenterology
ETHYPHARM is a pharmaceutical company focused on Infectious Disease, Cardiovascular, Gastroenterology. Key products include ESOMEPRAZOLE MAGNESIUM.
1969
Since
4
Drugs
-
Trials
130
Approved (2yr)
Recent Activity
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE 2026-01-21
BUPRENORPHINE HYDROCHLORIDE 2026-01-02
Labeling
BUPRENORPHINE HYDROCHLORIDE 2025-12-31
Labeling
BUPRENORPHINE HYDROCHLORIDE 2025-12-29
Labeling
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE 2025-12-22
Labeling
BUPRENORPHINE HYDROCHLORIDE 2025-12-22
Labeling
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE 2025-12-22
Labeling
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE 2025-12-22
Labeling
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE 2025-12-22
Labeling
BUPRENORPHINE HYDROCHLORIDE 2025-12-22
Labeling
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Infectious Disease 33%
1 drugs
Cardiovascular 33%
1 drugs
Gastroenterology 33%
1 drugs
Pipeline Strength Pro
Loading...
Competitors Pro
APOTHECON specialty
Infectious Disease, Cardiovascular, Gastroenterology
Pfizer big-pharma
Infectious Disease, Gastroenterology
WAYLIS THERAP big-pharma
Cardiovascular, Infectious Disease, Gastroenterology
Merck big-pharma
Infectious Disease, Cardiovascular
WARNER CHILCOTT LLC specialty
Cardiovascular, Gastroenterology, Infectious Disease
Discontinued (2)
Company Info
- First Approval
- 1969-07-29
- Latest
- 2025-12-22
- Applications
- 4